Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

URGN – UroGen Pharma Ltd.

Float Short %

26.03

Margin Of Safety %

Put/Call OI Ratio

0.33

EPS Next Q Diff

0.24

EPS Last/This Y

-0.17

EPS This/Next Y

2.16

Price

21.08

Target Price

35.25

Analyst Recom

1.25

Performance Q

-10.53

Upside

-674.8%

Beta

1.34

Ticker: URGN




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23URGN20.010.181.4622001
2026-01-26URGN21.070.180.2522100
2026-01-27URGN21.850.1816.5622170
2026-01-28URGN21.320.250.1023405
2026-01-29URGN20.680.250.0023299
2026-01-30URGN19.650.250.5923360
2026-02-02URGN19.660.254.7023386
2026-02-03URGN20.050.251.5023439
2026-02-04URGN20.710.2516.6723433
2026-02-05URGN20.540.260.0023630
2026-02-06URGN21.380.260.7223631
2026-02-09URGN21.940.300.0023577
2026-02-10URGN21.690.3016.7623591
2026-02-11URGN21.170.330.0124193
2026-02-12URGN20.250.330.0324162
2026-02-13URGN20.10.330.0424035
2026-02-17URGN20.630.330.1924140
2026-02-18URGN22.30.330.1324151
2026-02-19URGN21.840.330.2024281
2026-02-20URGN21.070.330.0324286
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-23URGN19.9938.9- -3.13
2026-01-26URGN21.0638.9- -3.13
2026-01-27URGN21.8638.9- -3.13
2026-01-28URGN21.3438.9- -3.13
2026-01-29URGN20.6638.9- -3.13
2026-01-30URGN19.6136.6- -3.13
2026-02-02URGN19.6736.6- -3.13
2026-02-03URGN20.0436.6- -3.13
2026-02-04URGN20.7336.6- -3.13
2026-02-05URGN20.5236.6- -3.13
2026-02-06URGN21.3836.6- -3.13
2026-02-09URGN21.9436.6- -3.13
2026-02-10URGN21.6836.6- -3.13
2026-02-11URGN21.1636.6- -3.13
2026-02-12URGN20.2536.6- -3.13
2026-02-13URGN20.1036.6- -3.13
2026-02-17URGN20.6036.6- -3.13
2026-02-18URGN22.3036.6- -3.13
2026-02-19URGN21.8236.6- -3.13
2026-02-20URGN21.0836.1- -3.13
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-23URGN-0.468.6724.66
2026-01-26URGN-0.468.4124.66
2026-01-27URGN-0.468.4124.66
2026-01-28URGN-0.468.4127.31
2026-01-29URGN-0.468.4127.31
2026-01-30URGN-0.468.4127.31
2026-02-02URGN-0.308.5227.31
2026-02-03URGN-0.308.5227.31
2026-02-04URGN-0.308.5227.31
2026-02-05URGN-0.398.5227.31
2026-02-06URGN-0.398.5227.31
2026-02-09URGN-0.398.9827.31
2026-02-10URGN-0.398.9827.31
2026-02-11URGN-0.488.9826.61
2026-02-12URGN-0.488.9826.61
2026-02-13URGN-0.488.9826.61
2026-02-17URGN-0.3616.1926.62
2026-02-18URGN-0.3616.1926.62
2026-02-19URGN-0.3616.1926.62
2026-02-20URGN-0.3616.1926.03
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

-0.69

Avg. EPS Est. Current Quarter

-0.49

Avg. EPS Est. Next Quarter

-0.45

Insider Transactions

-0.36

Institutional Transactions

16.19

Beta

1.34

Average Sales Estimate Current Quarter

41

Average Sales Estimate Next Quarter

45

Fair Value

Quality Score

22

Growth Score

49

Sentiment Score

77

Actual DrawDown %

29.7

Max Drawdown 5-Year %

-84.4

Target Price

35.25

P/E

Forward P/E

PEG

P/S

10.22

P/B

P/Free Cash Flow

EPS

-3.46

Average EPS Est. Cur. Y​

-3.13

EPS Next Y. (Est.)

-0.97

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-170.59

Relative Volume

0.74

Return on Equity vs Sector %

113.7

Return on Equity vs Industry %

131.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

UroGen Pharma Ltd.
Sector: Healthcare
Industry: Biotechnology
Employees: 287
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today
news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025
marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance
stock history URGN – UroGen Pharma Ltd. invest stock market
stock prices URGN premarket after hours
ticker URGN fair value insiders trading